Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multifocal recurrent neuralgic amyotrophy in an immunocompromised patient.
Briani C, Salvalaggio A, Anglani M, Imbergamo S, Pravato S, Marasca M, Cacciavillani M, Gasparotti R. Briani C, et al. Among authors: imbergamo s. J Neurol. 2024 Mar;271(3):1080-1083. doi: 10.1007/s00415-023-12157-4. Epub 2024 Jan 7. J Neurol. 2024. PMID: 38184820 No abstract available.
Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies.
Angotzi F, Petrella M, Berno T, Binotto G, Bonetto G, Branca A, Carraro M, Cavaretta CA, Cellini A, D'Amore F, Forlani L, Gianesello I, Gurrieri C, Imbergamo S, Lessi F, Maroccia A, Mazzetto F, Pavan L, Pezone S, Piazza F, Pravato S, Ruocco V, Scapinello G, Vianello F, Zambello R, Zatta I, Zoletto S, Padoan A, Trentin L, Visentin A. Angotzi F, et al. Among authors: imbergamo s. Front Oncol. 2023 Jun 22;13:1212752. doi: 10.3389/fonc.2023.1212752. eCollection 2023. Front Oncol. 2023. PMID: 37427126 Free PMC article.
A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody Deficiency.
Visentin A, Molinari MC, Pravato S, Cellini A, Angotzi F, Cavaretta CA, Ruocco V, Imbergamo S, Piazza F, Proietti G, Mauro FR, Trentin L. Visentin A, et al. Among authors: imbergamo s. Curr Oncol. 2022 Dec 25;30(1):274-283. doi: 10.3390/curroncol30010022. Curr Oncol. 2022. PMID: 36661671 Free PMC article.
Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy.
Voso MT, Pandzic T, Falconi G, Denčić-Fekete M, De Bellis E, Scarfo L, Ljungström V, Iskas M, Del Poeta G, Ranghetti P, Laidou S, Cristiano A, Plevova K, Imbergamo S, Engvall M, Zucchetto A, Salvetti C, Mauro FR, Stavroyianni N, Cavelier L, Ghia P, Stamatopoulos K, Fabiani E, Baliakas P. Voso MT, et al. Among authors: imbergamo s. Br J Haematol. 2022 Jul;198(1):103-113. doi: 10.1111/bjh.18129. Epub 2022 Mar 11. Br J Haematol. 2022. PMID: 35277855
Corrigendum to "Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience" [Leukemia Res. 114 (March 2022) 106803].
De Bellis E, Imbergamo S, Candoni A, Liço A, Tanasi I, Mauro E, Mosna F, Leoncin M, Stulle M, Griguolo D, Pravato S, Trentin L, Lazzarotto D, Di Bona E, Sancetta R, Lucchini E, Poiani M, Palmieri C, Zaja F. De Bellis E, et al. Among authors: imbergamo s. Leuk Res. 2022 Apr;115:106811. doi: 10.1016/j.leukres.2022.106811. Epub 2022 Feb 24. Leuk Res. 2022. PMID: 35219543 No abstract available.
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.
De Bellis E, Imbergamo S, Candoni A, Liço A, Tanasi I, Mauro E, Mosna F, Leoncin M, Stulle M, Griguolo D, Pravato S, Trentin L, Lazzarotto D, Di Bona E, Bassan R, Lucchini E, Poiani M, Palmieri C, Zaja F. De Bellis E, et al. Among authors: imbergamo s. Leuk Res. 2022 Mar;114:106803. doi: 10.1016/j.leukres.2022.106803. Epub 2022 Feb 8. Leuk Res. 2022. PMID: 35150967 Free article.
Sequential allogeneic transplantation and ruxolitinib maintenance for a synchronous PCM1-JAK2 positive myeloid sarcoma and acute B-lymphoblastic leukemia.
Rizzuto G, Leoncin M, Imbergamo S, Taurino D, Mico MC, Tosi M, Michelato A, Buklijas K, Spinelli O, Lussana F, Lessi F, Pizzi M, Bonaldi L, Binotto G, Rambaldi A, Gurrieri C. Rizzuto G, et al. Among authors: imbergamo s. Clin Case Rep. 2022 Jan 7;10(1):e05212. doi: 10.1002/ccr3.5212. eCollection 2022 Jan. Clin Case Rep. 2022. PMID: 35028141 Free PMC article.
Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia.
Frezzato F, Visentin A, Severin F, Pizzo S, Ruggeri E, Mouawad N, Martinello L, Pagnin E, Trimarco V, Tonini A, Carraro S, Pravato S, Imbergamo S, Manni S, Piazza F, Brunati AM, Facco M, Trentin L. Frezzato F, et al. Among authors: imbergamo s. Cancers (Basel). 2021 Oct 29;13(21):5453. doi: 10.3390/cancers13215453. Cancers (Basel). 2021. PMID: 34771616 Free PMC article.
Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia.
Visentin A, Frezzato F, Severin F, Imbergamo S, Pravato S, Romano Gargarella L, Manni S, Pizzo S, Ruggieri E, Facco M, Brunati AM, Semenzato G, Piazza F, Trentin L. Visentin A, et al. Among authors: imbergamo s. Onco Targets Ther. 2020 Sep 29;13:9679-9688. doi: 10.2147/OTT.S268899. eCollection 2020. Onco Targets Ther. 2020. PMID: 33061448 Free PMC article. Review.
28 results